Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus X TROZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus X TROZINE.
LIVOSTIN vs X-TROZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
X-TROZINE acts as a selective serotonin reuptake inhibitor (SSRI) by binding to the serotonin transporter (SERT) and blocking reuptake of serotonin, thereby increasing serotonergic neurotransmission.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Renal excretion accounts for 60-70% of total clearance, predominantly as unchanged drug. Biliary/fecal elimination constitutes 20-30% via P-glycoprotein-mediated transport. Minor metabolism (<10%) via CYP3A4.
Category C
Category C
Antihistamine
Antihistamine